Abstract 3793: Preventing nk cell activation in the damaged liver induced by cabozantinib/pd-1 blockade increases survival in hepatocellular carcinoma models
Research reveals that blocking NK cell activation improves survival in liver-damaged hepatocellular carcinoma models, indicating a potential treatment strategy.
Key Points
The study aims to understand why combining cabozantinib with immune checkpoint blockade fails in liver-damaged hepatocellular carcinoma.
Utilized orthotopic murine models of hepatocellular carcinoma with varying liver conditions.
Monitored tumor growth, liver function, and survival outcomes.
Conducted immune profiling of intra-tumoral and liver environments.
Cabozantinib/ICB treatment led to tumor regression and improved survival in normal liver conditions.
In mice with liver fibrosis, the combination treatment did not enhance survival despite similar tumor control.
Depletion of NK cells reduced hepatotoxicity and improved survival in liver-damaged mice receiving combination therapy.